Tubulysin M is primarily investigated for its potent antitumor properties, making it a promising candidate in cancer research. Its mechanism involves disrupting microtubule dynamics, which are crucial for cell division, thereby inhibiting the growth of cancer cells. This compound has shown significant cytotoxicity against various cancer cell lines, particularly in drug-resistant tumors, highlighting its potential in developing novel chemotherapeutic agents. Researchers are exploring its use in antibody-drug conjugates (ADCs), where it can be targeted specifically to cancer cells, minimizing damage to healthy tissues. Additionally, Tubulysin M is being studied for its role in overcoming multidrug resistance, a common challenge in cancer treatment. Its unique structure and activity profile make it a valuable tool in the development of next-generation cancer therapies.